| Metric | FY2025 | FY2024 |
|---|---|---|
| Total Revenue | $290K | $0 |
| Total Cost of Revenue | $509K+12055.7% | $4K |
| Gross Profit | $192K+8636.1% | $2K |
| General and administrative | $51K+71.4% | $30K |
| Advertising and promotion | $78K+114.1% | $37K |
| Clinical trial fees | $7K | $0 |
| Corporate filings | $19K | $0 |
| Equipment leases | $32K | $0 |
| Legal and professional fees | $138K+101.3% | $69K |
| Licenses | $3K | $0 |
| Public relations | $17K | $0 |
| Repairs and maintenance | $5K | $0 |
| Research and development | $29K | $0 |
| Rent | $65K+510.8% | $11K |
| Salaries and wages | $62K | $0 |
| Shared-based compensation | $42K+36.9% | $31K |
| Utilities | $6K | $0 |
| Depreciation and amortization | $4K+925.2% | $433 |
| Total Operating Expenses | $558K+215.4% | $177K |
| Profit (Loss) from Operations | -$366K-109.7% | -$175K |
| Interest income | $625 | $0 |
| Sublease income | $2K | $0 |
| Interest expense – line of credit (related party) | -$32K-400.1% | -$6K |
| Total Other Income (Expense) | -$29K-358.6% | -$6K |
| Net Loss Before Provision for Income Taxes | -$395K-118.4% | -$181K |
| Provision for Income Taxes | $0 | $0 |
| NET LOSS | -$395K-118.4% | -$181K |
| Net Loss Per Share: Basic | $0.00 | $0.00 |
| Net Loss Per Share: Diluted | $0.00 | $0.00 |
| Weighted Average Number of Shares Outstanding: Basic | 93.6M+2.0% | 91.7M |
| Weighted Average Number of Shares Outstanding: Diluted | 93.6M+2.0% | 91.7M |
| Sales Of Supplements [Member] | ||
| Medical Procedures [Member] | ||
| Sales Of Biologics [Member] | ||
| Sales Of Ancillary Products [Member] | ||
| Shipping And Delivery [Member] | ||
| Services [Member] | ||
| Supplements [Member] | ||
| Procedures [Member] | ||
| Biologics [Member] | ||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.